Pancreatitis Risk with TNF Inhibitors
Author Information
Author(s): Muacevic Alexander, Adler John R, Gu Joyce H, Samarneh Mark
Primary Institution: Lake Erie College of Osteopathic Medicine, Greensburg, USA
Hypothesis
Is there an increasing trend in pancreatitis risk associated with TNF inhibitor use?
Conclusion
The study found a significant increase in pancreatitis risk associated with TNF inhibitors, particularly in the year 2023.
Supporting Evidence
- IFX had the highest risk for pancreatitis with an ROR of 2.13.
- All TNF inhibitors showed an increasing trend in pancreatitis risk over the years.
- Statistically significant associations were observed for all TNF inhibitors in 2023.
- Female patients had a higher ROR for pancreatitis compared to male patients.
- Pediatric patients had a statistically higher ROR for pancreatitis compared to other age groups.
- Concomitant use of azathioprine was a significant confounding factor in the association with pancreatitis.
Takeaway
Using certain medications called TNF inhibitors can make people more likely to get a sickness called pancreatitis, especially in recent years.
Methodology
The study used a retrospective case-control design analyzing data from the FDA Adverse Event Reporting System (FAERS) database from 2012 to 2024.
Potential Biases
The FAERS database may contain selection biases due to being based on spontaneous adverse event reports.
Limitations
The study may not account for all confounding variables such as gallstones and alcohol use that can also cause pancreatitis.
Participant Demographics
The majority of adverse event reports were from females (998,044) compared to males (396,485), with a predominance in the adult population.
Statistical Information
P-Value
2.13 (for IFX)
Confidence Interval
95% CI, 2.02, 2.24
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website